Medindia
Advertisement

Survival Time for Treatments of Rare Eye Cancer Compared in New Study

by Thilaka Ravi on June 18, 2014 at 8:56 PM

Survival Time for Treatments of Rare Eye Cancer Compared in New Study
In patients with advanced uveal melanoma, treatment with the agent selumetinib, compared with chemotherapy, resulted in an improved cancer progression-free survival time and tumor response rate, but no improvement in overall survival, shows a study in the June 18 issue of JAMA.

The modest improvement in clinical outcomes was accompanied by a high rate of adverse events.
Advertisement

Uveal melanoma arises from melanocytes within the choroid layer of the eye. There are about 1,500 new cases of uveal melanoma per year in the U.S., which is biologically distinct from skin related melanoma. Selumetinib is an oral agent that may help to inhibit the growth of cancer cells by blocking MEK1/2.

A subgroup analysis from an earlier trial that included 20 patients with uveal melanoma suggested favorable results with selumetinib treatment, according to background information in the article.
Advertisement

Richard D. Carvajal, M.D., of Memorial Sloan-Kettering Cancer Center, New York, and colleagues randomly assigned patients with metastatic uveal melanoma to receive selumetinib (n = 50; orally twice daily), or chemotherapy (n = 51; temozolomide, orally daily for 5 of every 28 days, or dacarbazine, intravenously every 21 days) until disease progression, death, intolerable adverse effects, or withdrawal of consent.

After analysis of the primary outcome, 19 additional patients were registered and 18 treated with selumetinib without randomization, to complete the planned 120-patient enrollment. 1The researchers reported that the median progression-free survival time was 7 weeks in the chemotherapy group (median treatment duration, 8 weeks) and 15.9 weeks in the selumetinib group (median treatment duration, 16.1 weeks). The 4-month progression-free survival rate was 8.5 percent with chemotherapy, and 43.1 percent with selumetinib. Median overall survival time was 9.1 months with chemotherapy and 11.8 months with selumetinib, a difference that was not statistically significant.

Tumor regression was uncommon with chemotherapy, whereas 49 percent of patients randomized to selumetinib achieved tumor regression. Treatment-related adverse events were observed in 97 percent of patients treated with selumetinib, with 37 percent requiring at least 1 dose reduction. "In this hypothesis-generating study of patients with advanced uveal melanoma, selumetinib compared with chemotherapy resulted in a modestly improved progression-free survival time and rate of response; however, no improvement in overall survival was observed. Improvement in clinical outcomes was accompanied by a high rate of adverse events." the authors conclude.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Lower Respiratory Tract Infections Linked to Obstructive Sleep Apnea in Children
Type 2 Diabetes can be Controlled by Unripen Green Jackfruit Flour
Covid Pandemic: How Parents can Help Kids Deal with Back-to-School Anxiety
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Cancer and Homeopathy Retinoblastoma Cancer Facts Cancer Tattoos A Body Art Eye Vision LASIK Surgery Facts Allergy Eye Drops Routine Eye Examination 

Recommended Reading
Eye Pain Symptom Evaluation
Eye pain usually follows trauma, eye infection or inflammation of the eye and the surrounding ......
Eye Discharge Symptom Evaluation
Eye discharge usually indicates the presence of infection or allergy and should be promptly ......
Routine Eye Examination
A comprehensive eye exam can take an hour or more, depending on the doctor and the number and ......
Allergy Eye Drops
Eye allergies are treated with different types of eye drops such as lubricants, antihistamines, NSAI...
Retinoblastoma
Retinoblastoma is a type of cancer of the eye occurring in children. Early diagnosis and treatment, ...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use